Kurzübersicht für Rekombinanter Etanercept Biosimilar Antikörper (ABIN7795136)
Target
Etanercept Biosimilar
Antikörpertyp
Recombinant Antibody
Reaktivität
Human
Wirt
Maus
Klonalität
Monoklonal
Applikation
Flow Cytometry (FACS), In vivo Studies (in vivo)
Güteklasse
Research Grade
Expressionssystem
Mammalian cells
Verwendungszweck
Etanercept Biosimilar
Produktmerkmale
What is research grade Etanercept biosimilar? Research grade Etanercept biosimilar has the same amino acid sequence as Etanercept (trade name Enbrel), a fusion protein of the soluble TNF receptor 2 and a Fc fragment (human IgG1 isotype). Etanercept can be used to treat autoimmune diseases by interfering with tumor necrosis factor (TNF), a soluble inflammatory cytokine, by acting as a TNF inhibitor. TNF alpha is the "master regulator" of the inflammatory (immune) response in many organ systems. Autoimmune diseases are caused by an overactive immune response. Etanercept has the potential to treat these diseases by inhibiting TNF alpha. Etanercept binds to TNF alpha and decreases its role in disorders involving excess inflammation in humans and other animals, including autoimmune diseases such as ankylosing spondylitis, juvenile rheumatoid arthritis, psoriasis, psoriatic arthritis, rheumatoid arthritis, and, potentially, in a variety of other disorders mediated by excess TNF alpha.
Aufreinigung
Protein A or G affinity column
Reinheit
>95 % by reducing SDS-PAGE
Endotoxin-Niveau
< 1 EU per 1 mg of the protein by the LAL method
Applikationshinweise
Optimal working dilution should be determined by the investigator.
Beschränkungen
Nur für Forschungszwecke einsetzbar
Format
Liquid
Konzentration
> 3 mg/mL
Lagerung
4 °C,-20 °C
Informationen zur Lagerung
Short time 2 to 8°C as supplied. Long time -20°C to -70°C as supplied.